Novartis AG (NVS) Comparison with companies in other sectors?

Novartis AG has a share price of 1.95B. You can analyze Novartis AG (NVS) competitors across different market sectors through stock heatmaps.

What are NVS's NET and operating margins?

Novartis AG (NVS) operating margin is around 0.30, and net profit margin is approximately 0.18 as of the latest reports.

In what way does NVS's earnings per share (EPS) trend reflect its financial momentum?

Novartis AG (NVS) EPS is 6.86 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Novartis AG is 17.15, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Novartis AG?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Novartis AG like P/E which is 23.80, P/B which is 5.45, and PEG which is 3.000. Compare them with sector averages to evaluate if the stock is priced fairly.

Novartis AG

NVS•NYSE

Healthcare

Drug Manufacturers - General

$117.70

$0.24(0.20%)

Fundamental Analysis of Novartis AG (NVS)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$6.86

P/E Ratio

17.15

ROE

0.23%

Net Margin

0.18%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$228.96B

Shares OutstandingTotal number of shares issued

$1.95B

Book Value/ShareNet worth per share

$21.59

Revenue/ShareAnnual revenue per share

$28.04

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$6.86

Net MarginNet income as percentage of revenue

17.60%

Operating MarginOperating income as percentage of revenue

30.33%

ROEReturn on shareholders' equity

22.94%

ROAReturn on total assets

9.21%

ROCEReturn on capital employed

22.80%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$8.63

Cash/ShareCash and equivalents per share

$3.59

FCF YieldFree cash flow as percentage of market cap

7.35%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$3.99

Dividend YieldAnnual dividend as percentage of stock price

3.40%

Financial Ratios Analysis data is not available for NVSFinancial Ratios Analysis details for NVS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for NVSSector Benchmarking details for NVS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Novartis AG Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Novartis AG. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Novartis AG's unique business strengths and challenges.

Key Financial Metrics for Novartis AG

For Novartis AG, essential financial indicators include EPS 6.86, PE 17.15, and ROE 0.23. These key ratios reveal insights into Novartis AG's profitability, valuation, and operational health. Understanding these metrics enables you to compare Novartis AG with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Novartis AG

Metrics like Net Margin 17.60% and ROA 9.21% shed light on how well Novartis AG is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Novartis AG can sustain its operations and continue growing in the future.

Valuation and Market Position of Novartis AG

Using ratios such as P/B Ratio 5.45 and PEG Ratio 3.000, investors can assess whether Novartis AG is appropriately valued based on its financials and growth potential. These figures, combined with Novartis AG's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Novartis AG

Financial health indicators, such as Debt/Equity Ratio 0.78 and Cash Flow $8.63, provide a snapshot of Novartis AG's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Novartis AG, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Novartis AG

Investing in Novartis AG based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Novartis AG focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;